The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: A systematic review of clinical trials

Cancer Gene Therapy

Volumn 24, Issue 5, 2017, Pages 189-193

  Ansari, L ^a   Shiehzadeh, F ^a   Taherzadeh, Z ^b   Nikoofal Sahlabadi, S ^a   Momtazi Borojeni, A A ^a   Sahebkar, A ^c,d   Eslami, S ^e,f  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ANTINEOPLASTIC ANTIBIOTIC; MACROGOL DERIVATIVE;

ABDOMINAL PAIN; ALOPECIA; ANEMIA; ANOREXIA; ASTHENIA; BONE PAIN; CARDIOTOXICITY; CONSTIPATION; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERPIGMENTATION; INFECTION; LEUKOPENIA; LUNG EMBOLISM; LYMPHOCYTOPENIA; METASTATIC BREAST CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; MUSCULOSKELETAL PAIN; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOSIS; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; BREAST TUMOR; CHEMICALLY INDUCED; HEART DISEASE; METASTASIS; PATHOLOGY; SKIN DISEASE;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; DOXORUBICIN; FEMALE; HEART DISEASES; HUMANS; NAUSEA; NEOPLASM METASTASIS; POLYETHYLENE GLYCOLS; SKIN DISEASES;

EID: 85017454926     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2017.9     Document Type: Review

References (18)

1. Mlineritsch B, Mayer P, Rass C, Reiter E, Russ G, Vesenmayer G et al. Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure. Onkologie 2004; 27: 441-446.
2. Gebbia V, Mauceri G, Fallica G, Borsellino N, Tirrito ML, Testa A et al. Pegylated liposomal doxorubicin with vinorelbine in metastatic breast carcinoma. A phase I-II clinical investigation. Oncology 2002; 63: 23-30.
3. Mlineritsch B, Schabel-Moser R, Andel J, Fridrik M, Moik M, Mayer P et al. Multicenter phase II study of pegylated liposomal doxorubicin in combination with vinorelbine as first-line treatment in elderly patients with metastatic breast cancer. Onkologie 2009; 32: 18-24.
4. Alexopoulos A, Karamouzis MV, Stavrinides H, Ardavanis A, Kandilis K, Stavrakakis J et al. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer. Ann Oncol 2004; 15: 891-895.
5. Verma S, Dent S, Chow BJ, Rayson D, Safra T. Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines. Cancer Treat Rev 2008; 34: 391-406.
6. Coleman RE, Biganzoli L, Canney P, Dirix L, Mauriac L, Chollet P et al. A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993). Eur J Cancer 2006; 42: 882-887.
7. Krishna R, Mayer LD. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR). Anticancer Res 1999; 19: 2885-2891.
8. O'Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-449.
9. Falandry C, Brain E, Bonnefoy M, Mefti F, Jovenin N, Rigal O et al. Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial. Eur J Cancer 2013; 49: 2806-2814.
10. O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008; 19: 1-7.
11. Lao J, Madani J, Puertolas T, Alvarez M, Hernandez A, Pazo-Cid R et al. Liposomal doxorubicin in the treatment of breast cancer patients: a review. J Drug Deliv 2013; 2013; 456409.
12. Addeo R, Faiola V, Guarrasi R, Montella L, Vincenzi B, Capasso E et al. Liposomal pegylated doxorubicin plus vinorelbine combination as first-line chemotherapy for metastatic breast cancer in elderly women 4 or = 65 years of age. Cancer Chemother Pharmacol 2008; 62: 285-292.
13. Caraglia M, Addeo R, Costanzo R, Montella L, Faiola V, Marra M et al. Phase II study of temozolomide plus pegylated liposomal doxorubicin in the treatment of brain metastases from solid tumours. Cancer Chemother Pharmacol 2006; 57: 34-39.
14. Rivera E, Valero V, Esteva FJ, Syrewicz L, Cristofanilli M, Rahman Z et al. Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer. Cancer Chemother Pharmacol 2002; 49: 299-302.
15. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-3191.
16. Al-Batran SE, Meerpohl HG, von Minckwitz G, Atmaca A, Kleeberg U, Harbeck N et al. Reduced incidence of severe palmar-plantar erythrodysesthesia and mucositis in a prospective multicenter phase II trial with pegylated liposomal doxorubicin at 40 mg/m2 every 4 weeks in previously treated patients with metastatic breast cancer. Oncology 2006; 70: 141-146.
17. Al-Batran SE, Bischoff J, von Minckwitz G, Atmaca A, Kleeberg U, Meuthen I et al. The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 2006; 94: 1615-1620.
18. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma. Cancer 2000; 89: 1037-1047.